期刊文献+

乳腺良恶性疾病患者血清催乳素、雌二醇水平的比较及其临床意义 被引量:4

下载PDF
导出
摘要 目的:比较乳腺良恶性疾病患者雌二醇(E2)、催乳素(PRL)的水平,并探讨其临床意义。方法:采用放射免疫法分别测定44例乳腺癌患者术前、术后和17例乳腺良性疾病患者体内PRL、E2水平,并进行比较。结果:乳腺癌患者术后1周PRL均高于乳腺癌术前和术后4~12个月及乳腺良性疾病患者(P<0.01)。乳腺癌术后1周和术后4~12个月E2均低于术前(P<0.05)及乳腺良性疾病患者(P<0.05)。结论:PRL、E2水平升高可能是乳腺癌患者的发病原因之一;手术可使PRL暂时性升高而后下降,使雌激素下降;监测乳腺癌患者手术治疗后的PRL水平可能有助于早期发现乳腺癌复发或转移。
出处 《蚌埠医学院学报》 CAS 2013年第8期1005-1006,共2页 Journal of Bengbu Medical College
  • 相关文献

参考文献6

  • 1进淑娟,黄焰,刘广贤,孙雪冬,谭燕,霍芳,马宏宾.人乳腺珠蛋白mRNA在腋窝淋巴结及外周血中的表达规律及其临床意义[J].军事医学科学院院刊,2010,34(5):440-443. 被引量:7
  • 2Ferro P, Franceschini MC, Bacigalupo B, et al. Detection of circu- lating tumour cells in breast cancer patients using human mamma- globin RT-PCT: association with clinical prognostic factors [ J ]. Anticancer Res,2010,30(6) :2377 -2382.
  • 3黄雄,马桢,谢文彪.原发性乳腺癌组织中人乳腺珠蛋白的表达及意义[J].肿瘤防治研究,2010,37(6):667-670. 被引量:6
  • 4Chen Y, Zou TN, Wu ZP, et al. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen positive circulating tumor cells by threemarker reverse transcription RT-PCR assay and its relation to clinical outcome in early breast cancer[J]. Int J Bio Markers,2010,25 (2) :59 -68.
  • 5Roncella S, Ferro P, Franceschini MC, et al. Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin [ J ]. Diagn Mol Pathol, 2010,19(2) :92 -98.
  • 6Raica M, Cimpean AM, Meche A, et al. Analysis of the immuno- histochemical expression of mammaglobin A in primary breastearcinoma and lymph node metastasis [ J ]. Rom J Morphol Embryol.2009,50(3 ) :341 - 347.

二级参考文献20

  • 1Eiichi Sasaki, Nobuyuki Tsunoda, Yasushi Yatabe, et al. Breast-specific expression of MGB/mammaglobin: an exami nation of 480 tumors from various organs and clinicopathologi cal analysis of MGB-positive breast cancers[J]. ModernPathology,2007,20(2) :208 -214.
  • 2Jae-Ho Han, Yup Kang, Shin HC, et al. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma[J].Arch Pathol Lab, 2003, 127 ( 10 ) : 1330- 1334.
  • 3Colpitts TL, Billing P, Granados E, et al. mammaglobin complexes with BU 101 in breast tissue[J].Ann N Y Acad Sci, 2000,923:312 -315.
  • 4Goedegebuure PS, Watson MA, Viehl CT, et al. mammaglobin-based strategies for treatment of breast cancer[J]. Current Cancer Drug Targets, 2004,4 (6) : 531-542.
  • 5Pier Francesco Ferrucci, Cristina Rabascio, Chiara Mazzetta, et al. Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High- Risk Breast Cancer [J].Clinical Cancer Research, 2004, 10 (18pt1 ) : 6039-6046.
  • 6Paul N. Span, Esm Waanders,Peggy Manders, et al. Mammaglobin Is Associated With Low-Grade, Steroid Receptor Posi tive Breast Tumors From Postmenopausal Patients, and Has Independent Prognostic Value for Relapse-Free Survival Time [J]. Journal Of Clinical Ontology, 2004,22 (4) : 691-698.
  • 7Wang Z, Spaulding B, Sienko A, et al. Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma[J]. Int J Clin Exp Pathol,2009,2(4)384- 389.
  • 8Zuo L, Li L, Wang Q,et al. Mammaglobin as a potential molecular target for breast cancer drug delivery[J]. Cancer Cell Int,2009,9:8.
  • 9Waston MA, Fleming TP, Dintzis S, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer[J]. Cancer Res, 1999,59(13) :3028-3031.
  • 10Koga T, Horio Y, Mitsudomi T, et al. Identification of hMAM as a marker in the differential diagnosis of lung tumors in patients with a history of breast cancer by analysis of publicly available SAGE data[J]. J Mol Diagn, 2006,8(3)391-393.

共引文献9

同被引文献36

  • 1钟历勇.垂体催乳素瘤的临床特征与诊疗决策[J].中华临床医师杂志(电子版),2011,5(13):3702-3708. 被引量:8
  • 2李永健(综述),邸若虹(审校),陈红风(审校).催乳素、催乳素受体与乳腺癌[J].世界肿瘤杂志,2005,4(3):224-226. 被引量:4
  • 3Clevenger CV,Furth PA,Hankinson SE,et al.The role of prolactin in mammary carcinoma[J].Endocr Rev,2003,24(1):1-27.
  • 4Tworoger SS,Hankinson SE.Prolactin and breast cancer risk[J].Cancer Lett,2006,243(2):160-169.
  • 5Tworoger SS,Sluss P,Hankinson SE.Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women[J].Cancer Res,2006,66(4):2476-2482.
  • 6Tworoger SS,Eliassen AH,Sluss P,et al.A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer[J].J Clin Oncol,2007,25(12):1482-1488.
  • 7Tworoger SS,Eliassen AH,Zhang XH,et al.A 20-Year Prospective Study of Plasma Prolactin as a Risk Marker of Breast Cancer Development[J].Cancer Res,2013,73(5):4810-4819.
  • 8Tikk K,Sookthai D,Johnson T,et al.Circulating prolactin and breast cancer risk among pre-and postmenopausal women in the EPIC cohort[J].Ann Oncol,2014,25(7):1422-1428.
  • 9Bhatavdekar JM,Patel DD,Shah NG,et al.Prolactin as a local growth promoter in patients with breast cancer:GCRI experience[J].Eur J Surg Oncol,2000,26(6):540-547.
  • 10Llovera M,Touraine P,Kelly PA,et al.Involvement of prolactin in breast cancer:redefining the molecular targets[J].Exp Gerontol,2000,35(1):41-51.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部